Movement Alert｜HANSOH PHARMA Intraday Rise 3.3% in Regular Trading, Innovation Drug Names Advance as ADC Out-licensing Theme Stays in Focus

Market Focus10-29

On October 29, HANSOH PHARMA posted an Intraday Rise of 3.3% in Regular Trading, with the shares trading at HK$33.24 and turnover at HK$197 million.

The move is broadly consistent with continued strength in Hong Kong-listed innovation drug names, while market attention remains on Chinese biotech out-licensing themes, particularly ADC and bispecific assets.

Recent developments around the company remain centered on its expanded strategic ADC collaboration and licensing deal with Roche. Under the agreement, covering two preclinical ADC programs and additional platform-based projects, HANSOH PHARMA will receive a $400 million upfront payment and a $110 million first-anniversary payment, and is eligible for more than $15 billion in potential milestone payments plus tiered royalties. Several brokers have said the transaction validates the companys ADC platform competitiveness and improves visibility on global value monetization. More recently, positive ESMO data on Mo-Rez and HS-20122 also supported sentiment toward its oncology pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180397060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-29 13:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180397060","market":"us","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Intraday Rise 3.3% in Regular Trading, Innovation Drug Names Advance as ADC Out-licensing Theme Stays in Focus","media":"Market Focus","content":"<p><p>On October 29, HANSOH PHARMA posted an Intraday Rise of 3.3% in Regular Trading, with the shares trading at HK$33.24 and turnover at HK$197 million.</p><p>The move is broadly consistent with continued strength in Hong Kong-listed innovation drug names, while market attention remains on Chinese biotech out-licensing themes, particularly ADC and bispecific assets.</p><p>Recent developments around the company remain centered on its expanded strategic ADC collaboration and licensing deal with Roche. Under the agreement, covering two preclinical ADC programs and additional platform-based projects, HANSOH PHARMA will receive a $400 million upfront payment and a $110 million first-anniversary payment, and is eligible for more than $15 billion in potential milestone payments plus tiered royalties. Several brokers have said the transaction validates the companys ADC platform competitiveness and improves visibility on global value monetization. More recently, positive ESMO data on Mo-Rez and HS-20122 also supported sentiment toward its oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Intraday Rise 3.3% in Regular Trading, Innovation Drug Names Advance as ADC Out-licensing Theme Stays in Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Intraday Rise 3.3% in Regular Trading, Innovation Drug Names Advance as ADC Out-licensing Theme Stays in Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-29 13:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 29, HANSOH PHARMA posted an Intraday Rise of 3.3% in Regular Trading, with the shares trading at HK$33.24 and turnover at HK$197 million.</p><p>The move is broadly consistent with continued strength in Hong Kong-listed innovation drug names, while market attention remains on Chinese biotech out-licensing themes, particularly ADC and bispecific assets.</p><p>Recent developments around the company remain centered on its expanded strategic ADC collaboration and licensing deal with Roche. Under the agreement, covering two preclinical ADC programs and additional platform-based projects, HANSOH PHARMA will receive a $400 million upfront payment and a $110 million first-anniversary payment, and is eligible for more than $15 billion in potential milestone payments plus tiered royalties. Several brokers have said the transaction validates the companys ADC platform competitiveness and improves visibility on global value monetization. More recently, positive ESMO data on Mo-Rez and HS-20122 also supported sentiment toward its oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1180397060","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180397060","pubTimestamp":1793251131,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 29, HANSOH PHARMA posted an Intraday Rise of 3.3% in Regular Trading, with the shares trading at HK$33.24 and turnover at HK$197 million.The move is broadly consistent with continued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"动向提醒|豪森制药盘中常规交易涨3.3%，创新药品种领涨，ADC外授权主题持续聚焦","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On October 29, HANSOH PHARMA posted an Intraday Rise of 3.3% in Regular Trading, with the shares trading at HK$33.24 and turnover at HK$197 million.The move is broadly consistent with continued strength in Hong Kong-listed innovation drug names, while market attention remains on Chinese biotech out-licensing themes, particularly ADC and bispecific assets.Recent developments around the company remain centered on its expanded strategic ADC collaboration and licensing deal with Roche. Under the agreement, covering two preclinical ADC programs and additional platform-based projects, HANSOH PHARMA will receive a $400 million upfront payment and a $110 million first-anniversary payment, and is eligible for more than $15 billion in potential milestone payments plus tiered royalties. Several brokers have said the transaction validates the companys ADC platform competitiveness and improves visibility on global value monetization. More recently, positive ESMO data on Mo-Rez and HS-20122 also supported sentiment toward its oncology pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180397060","isCrawlerRequest":true}